{"id":11385823,"date":"2025-09-29T20:54:24","date_gmt":"2025-09-29T17:54:24","guid":{"rendered":"https:\/\/nostylelike.net\/?post_type=product&p=11385823"},"modified":"2026-05-14T15:51:31","modified_gmt":"2026-05-14T12:51:31","slug":"actemra-tocilizumab","status":"publish","type":"product","link":"https:\/\/nostylelike.net\/en\/product\/actemra-tocilizumab\/","title":{"rendered":"Actemra (Tocilizumab) Injection \u2013 80mg, 200mg, 400mg & 162mg for Rheumatoid Arthritis | No Style Like"},"content":{"rendered":"

Introduction:<\/strong><\/h2>\n

Are you struggling with chronic joint pain, swelling, and stiffness caused by autoimmune inflammation?
Meet Actemra (Tocilizumab)<\/strong> \u2014 a breakthrough biologic therapy from Roche<\/strong>, designed to target interleukin-6 (IL-6)<\/strong>, one of the key drivers of inflammation in rheumatoid arthritis<\/strong> and related conditions.
This article explores all available Actemra formulations<\/strong> (80mg\/4ml, 200mg\/10ml, 400mg\/20ml IV vials, and 162mg\/0.9ml prefilled syringes), their uses, dosage, safety profile, and benefits \u2014 helping you understand which option best fits your treatment plan.<\/p>\n

\n

What is Actemra (Tocilizumab)?<\/strong><\/h2>\n

Actemra<\/strong> is a monoclonal antibody<\/strong> medication that blocks interleukin-6 receptors (IL-6R)<\/strong>. By doing so, it reduces inflammation, joint damage, and pain in autoimmune diseases.
It\u2019s FDA-approved for rheumatoid arthritis (RA)<\/strong>, juvenile idiopathic arthritis (JIA)<\/strong>, and giant cell arteritis (GCA)<\/strong>, and has been used under strict medical supervision for severe COVID-19 pneumonia<\/strong>.<\/p>\n

\n

Actemra Available Forms & Concentrations:<\/strong><\/h2>\n

Actemra 80mg\/4ml Vial<\/h3>\n